These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36258935)

  • 1. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
    Gagliardi TA; Milner J; Cairo MS; Steinberg A
    Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
    Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
    Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
    Martini DJ; Chen YB; DeFilipp Z
    Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Jaglowski SM; Blazar BR
    Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
    Linn SM; Novitzky-Basso I; Abduljalil O; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Kim DDH
    Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):60-71. PubMed ID: 37581458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
    Zeiser R
    J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
    [No Abstract]   [Full Text] [Related]  

  • 12. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
    Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
    Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Rahmat LT; Logan AC
    Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
    Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
    Front Immunol; 2022; 13():954268. PubMed ID: 35990629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Toubai T; Hosokawa Y
    Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.